Publications

• Investigation of the protein corona and biodistribution profile of polymeric nanoparticles for intra-amniotic delivery.Lynn AY, Shin K, Eaton DA, Rose M, Zhang X, Ene M, Grundler J, Deschenes E, Rivero R, Bracaglia LG, Glazer PM, Stitelman DH, Saltzman WM. Biomaterials. 2025 Sep; 2025 Mar 6. PMID: 40064138.
• Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate.Yurkevicz AM, Liu Y, Katz SG, Glazer PM. Mol Cancer Ther. 2025 Jan 2. PMID: 39382073.
• Biodistribution of Polymeric Nanoparticles following in utero Delivery to a Nonhuman Primate.Eaton DA, Lynn AY, Surprenant JM, Deschenes EI, Guerra ME, Rivero R, Yung NK, O'Connor M, Glazer PM, Bahtiyar MO, Saltzman WM, Stitelman DH. Biomed Hub. 2025 Jan-Dec; 2024 Dec 12. PMID: 39845408.
• Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation.Gupta A, Barone C, Quijano E, Piotrowski-Daspit AS, Perera JD, Riccardi A, Jamali H, Turchick A, Zao W, Saltzman WM, Glazer PM, Egan ME. J Cyst Fibros. 2025 Jan; 2024 Aug 5. PMID: 39107154.
• Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition.Rackear M, Quijano E, Ianniello Z, Colón-Ríos DA, Krysztofiak A, Abdullah R, Liu Y, Rogers FA, Ludwig DL, Dwivedi R, Bleichert F, Glazer PM. Oncotarget. 2024 Oct 1; 2024 Oct 1. PMID: 39352803.
• Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity.Carufe KEW, Economos NG, Glazer PM. Nucleic Acid Ther. 2024 Oct; 2024 Jul 22. PMID: 39037032.
• Systemic in utero gene editing as a treatment for cystic fibrosis.Ricciardi AS, Barone C, Putman R, Quijano E, Gupta A, Nguyen R, Mandl H, Piotrowski-Daspit AS, Lopez-Giraldez F, Luks V, Freedman-Weiss MR, Farrelly J, Ahle S, Glazer PM, Saltzman WM, Stitelman DH, Egan ME. bioRxiv. 2024 Sep 8; 2024 Sep 8. PMID: 39282330.
• Genome scale CRISPR screens identify actin capping proteins as key modulators of therapeutic responses to radiation and immunotherapy.Verma N, Renauer PA, Dong C, Xin S, Lin Q, Zhang F, Glazer PM, Chen S. bioRxiv. 2024 Jan 15; 2024 Jan 15. PMID: 38293095.
• Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair.Altwerger G, Ghazarian M, Glazer PM. Semin Cancer Biol. 2024 Jan; 2023 Nov 28. PMID: 38029867.
• Head-to-head comparison of in vitro and in vivo efficacy of pHLIP-conjugated anti-seed gamma peptide nucleic acids.Dhuri K, Duran T, Chaudhuri B, Slack FJ, Vikram A, Glazer PM, Bahal R. Cell Rep Phys Sci. 2023 Oct 18; 2023 Sep 15. PMID: 38144419.
• DNA recognition and induced genome modification by a hydroxymethyl-γ tail-clamp peptide nucleic acid.Oyaghire SN, Quijano E, Perera JDR, Mandl HK, Saltzman WM, Bahal R, Glazer PM. Cell Rep Phys Sci. 2023 Oct 18. PMID: 37920723.
• Acetylation of MLH1 by CBP increases cellular DNA mismatch repair activity.Zhang M, Zhao J, Glazer PM, Bai W, Bepler G, Zhang XM. J Biochem. 2023 Jul 31. PMID: 37094360.
• Nanoparticle-mediated genome editing in single-cell embryos via peptide nucleic acids.Putman R, Ricciardi AS, Carufe KEW, Quijano E, Bahal R, Glazer PM, Saltzman WM. Bioeng Transl Med. 2023 May; 2022 Dec 2. PMID: 37206203.
• Response to: Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effect.Takahashi T, Stoiljkovic M, Song E, Gao XB, Yasumoto Y, Kudo E, Carvalho F, Kong Y, Park A, Shanabrough M, Szigeti-Buck K, Liu ZW, Kristant A, Zhang Y, Sulkowski P, Glazer PM, Kaczmarek LK, Horvath TL, Iwasaki A. Neuron. 2023 Mar 1. PMID: 36863323.
• Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide.Singh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Pediatr Blood Cancer. 2023 Mar; 2022 Sep 24. PMID: 36151992.
• Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. J Clin Oncol. 2023 Feb 1; 2022 Oct 18. PMID: 36256912.
• LINE-1 activation in the cerebellum drives ataxia.Takahashi T, Stoiljkovic M, Song E, Gao XB, Yasumoto Y, Kudo E, Carvalho F, Kong Y, Park A, Shanabrough M, Szigeti-Buck K, Liu ZW, Kristant A, Zhang Y, Sulkowski P, Glazer PM, Kaczmarek LK, Horvath TL, Iwasaki A. Neuron. 2022 Oct 19; 2022 Sep 6. PMID: 36070749.
• In vivo correction of cystic fibrosis mediated by PNA nanoparticles.Piotrowski-Daspit AS, Barone C, Lin CY, Deng Y, Wu D, Binns TC, Xu E, Ricciardi AS, Putman R, Garrison A, Nguyen R, Gupta A, Fan R, Glazer PM, Saltzman WM, Egan ME. Sci Adv. 2022 Oct 7; 2022 Oct 5. PMID: 36197984.
• An ELISA-based platform for rapid identification of structure-dependent nucleic acid-protein interactions detects novel DNA triplex interactors.Economos NG, Thapar U, Balasubramanian N, Karras GI, Glazer PM. J Biol Chem. 2022 Oct; 2022 Aug 18. PMID: 35988651.
• Antispacer peptide nucleic acids for sequence-specific CRISPR-Cas9 modulation.Economos NG, Quijano E, Carufe KEW, Perera JDR, Glazer PM. Nucleic Acids Res. 2022 Jun 10. PMID: 35235944.
• Correction to 'Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity'.Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA, Engelman DM, Glazer PM, Bindra RS, Paralkar VM. NAR Cancer. 2021 Dec; 2021 Dec 7. PMID: 34888524.
• Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair.Dow J, Krysztofiak A, Liu Y, Colon-Rios DA, Rogers FA, Glazer PM. Mol Cancer Res. 2021 Dec; 2021 Sep 17. PMID: 34535560.
• Peptide nucleic acids and their role in gene regulation and editing.Perera JDR, Carufe KEW, Glazer PM. Biopolymers. 2021 Dec; 2021 Jun 15. PMID: 34129732.
• Regulation of the Cell-Intrinsic DNA Damage Response by the Innate Immune Machinery.Hayman TJ, Glazer PM. Int J Mol Sci. 2021 Nov 25; 2021 Nov 25. PMID: 34884568.
• BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.Raimundo L, Paterna A, Calheiros J, Ribeiro J, Cardoso DSP, Piga I, Neto SJ, Hegan D, Glazer PM, Indraccolo S, Mulhovo S, Costa JL, Ferreira MU, Saraiva L. Br J Pharmacol. 2021 Sep; 2021 Jun 11. PMID: 33899955.
• Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.Kim JW, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer PM, Shyr Y, Ivy SP, LoRusso PM. Oncologist. 2021 Jul; 2021 May 5. PMID: 33742489.
• Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity.Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA, Engelman DM, Glazer PM, Bindra RS, Paralkar VM. NAR Cancer. 2021 Jun; 2021 Jun 4. PMID: 34316708.
• The NIH Somatic Cell Genome Editing program.Saha K, Sontheimer EJ, Brooks PJ, Dwinell MR, Gersbach CA, Liu DR, Murray SA, Tsai SQ, Wilson RC, Anderson DG, Asokan A, Banfield JF, Bankiewicz KS, Bao G, Bulte JWM, Bursac N, Campbell JM, Carlson DF, Chaikof EL, Chen ZY, Cheng RH, Clark KJ, Curiel DT, Dahlman JE, Deverman BE, Dickinson ME, Doudna JA, Ekker SC, Emborg ME, Feng G, Freedman BS, Gamm DM, Gao G, Ghiran IC, Glazer PM, Gong S, Heaney JD, Hennebold JD, Hinson JT, Khvorova A, Kiani S, Lagor WR, Lam KS, Leong KW, Levine JE, Lewis JA, Lutz CM, Ly DH, Maragh S, McCray PB Jr, McDevitt TC, Mirochnitchenko O, Morizane R, Murthy N, Prather RS, Ronald JA, Roy S, Roy S, Sabbisetti V, Saltzman WM, Santangelo PJ, Segal DJ, Shimoyama M, Skala MC, Tarantal AF, Tilton JC, Truskey GA, Vandsburger M, Watts JK, Wells KD, Wolfe SA, Xu Q, Xue W, Yi G, Zhou J. Nature. 2021 Apr; 2021 Apr 7. PMID: 33828315.
• Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance.Dong YL, Vadla GP, Lu JJ, Ahmad V, Klein TJ, Liu LF, Glazer PM, Xu T, Chabu CY. Commun Biol. 2021 Mar 19; 2021 Mar 19. PMID: 33742110.
• Nanoparticles for delivery of agents to fetal lungs.Ullrich SJ, Freedman-Weiss M, Ahle S, Mandl HK, Piotrowski-Daspit AS, Roberts K, Yung N, Maassel N, Bauer-Pisani T, Ricciardi AS, Egan ME, Glazer PM, Saltzman WM, Stitelman DH. Acta Biomater. 2021 Mar 15; 2021 Jan 21. PMID: 33484911.
• Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides.Dharmaratne NU, Kaplan AR, Glazer PM. Cells. 2021 Mar 4; 2021 Mar 4. PMID: 33806273.
• Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway.Lu Y, Liu Y, Oeck S, Zhang GJ, Schramm A, Glazer PM. Cancer Res. 2020 Nov 1; 2020 Sep 1. PMID: 32873635.
• Oncometabolites suppress DNA repair by disrupting local chromatin signalling.Sulkowski PL, Oeck S, Dow J, Economos NG, Mirfakhraie L, Liu Y, Noronha K, Bao X, Li J, Shuch BM, King MC, Bindra RS, Glazer PM. Nature. 2020 Jun; 2020 Jun 3. PMID: 32494005.
• Ku80-Targeted pH-Sensitive Peptide-PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing Radiation.Kaplan AR, Pham H, Liu Y, Oyaghire S, Bahal R, Engelman DM, Glazer PM. Mol Cancer Res. 2020 Jun; 2020 Feb 25. PMID: 32098827.
• Impact of hypoxia on DNA repair and genome integrity.Kaplan AR, Glazer PM. Mutagenesis. 2020 Feb 13. PMID: 31282537.
• Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair.Economos NG, Oyaghire S, Quijano E, Ricciardi AS, Saltzman WM, Glazer PM. Molecules. 2020 Feb 8; 2020 Feb 8. PMID: 32046275.
• Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.Svoronos AA, Bahal R, Pereira MC, Barrera FN, Deacon JC, Bosenberg M, DiMaio D, Glazer PM, Engelman DM. Mol Pharm. 2020 Feb 3; 2020 Jan 13. PMID: 31855437.
• Pharmacological methods to transcriptionally modulate double-strand break DNA repair.Kaplan AR, Glazer PM. Int Rev Cell Mol Biol. 2020; 2019 Dec 18. PMID: 32475473.
• Poly(Lactic-co-Glycolic Acid) Nanoparticle Delivery of Peptide Nucleic Acids In Vivo.Oyaghire SN, Quijano E, Piotrowski-Daspit AS, Saltzman WM, Glazer PM. Methods Mol Biol. 2020. PMID: 32088877.
• Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response.Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García-Milian R, Mehta S, Reshetnyak YK, Bahal R, Fiorina P, Glazer PM, Rimm DL, Fernández-Hernando C, Suárez Y. J Clin Invest. 2019 Dec 2. PMID: 31710308.
• Mitochondrial DNA Stress Signalling Protects the Nuclear Genome.Wu Z, Oeck S, West AP, Mangalhara KC, Sainz AG, Newman LE, Zhang XO, Wu L, Yan Q, Bosenberg M, Liu Y, Sulkowski PL, Tripple V, Kaech SM, Glazer PM, Shadel GS. Nat Metab. 2019 Dec; 2019 Dec 9. PMID: 32395698.
• Optimizing biodegradable nanoparticle size for tissue-specific delivery.Mandl HK, Quijano E, Suh HW, Sparago E, Oeck S, Grun M, Glazer PM, Saltzman WM. J Control Release. 2019 Nov 28; 2019 Oct 22. PMID: 31654688.
• Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM. Sci Transl Med. 2019 May 15. PMID: 31092693.
• High-throughput Evaluation of Protein Migration and Localization after Laser Micro-Irradiation.Oeck S, Malewicz NM, Krysztofiak A, Turchick A, Jendrossek V, Glazer PM. Sci Rep. 2019 Feb 28; 2019 Feb 28. PMID: 30816253.
• Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells.Turchick A, Liu Y, Zhao W, Cohen I, Glazer PM. Oncotarget. 2019 Feb 12; 2019 Feb 12. PMID: 30863489.
• Electron-Mediated Aminyl and Iminyl Radicals from C5 Azido-Modified Pyrimidine Nucleosides Augment Radiation Damage to Cancer Cells.Wen Z, Peng J, Tuttle PR, Ren Y, Garcia C, Debnath D, Rishi S, Hanson C, Ward S, Kumar A, Liu Y, Zhao W, Glazer PM, Liu Y, Sevilla MD, Adhikary A, Wnuk SF. Org Lett. 2018 Dec 7; 2018 Nov 20. PMID: 30457873.
• Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.Xu Y, Taylor P, Andrade J, Ueberheide B, Shuch B, Glazer PM, Bindra RS, Moran MF, Linehan WM, Neel BG. Cancer Res. 2018 Dec 1; 2018 Oct 8. PMID: 30297534.
• Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.Lu Y, Liu Y, Oeck S, Glazer PM. Mol Cancer Res. 2018 Oct; 2018 Jun 22. PMID: 29934325.
• Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, Niger M, Boeke M, Ueno D, Kalathil AN, Bao X, Li J, Shuch B, Bindra RS, Glazer PM. Nat Genet. 2018 Aug; 2018 Jul 16. PMID: 30013182.
• PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF.Sulkowski PL, Scanlon SE, Oeck S, Glazer PM. Mol Cancer Res. 2018 Aug; 2018 May 8. PMID: 29739874.
• In utero nanoparticle delivery for site-specific genome editing.Ricciardi AS, Bahal R, Farrelly JS, Quijano E, Bianchi AH, Luks VL, Putman R, López-Giráldez F, Coşkun S, Song E, Liu Y, Hsieh WC, Ly DH, Stitelman DH, Glazer PM, Saltzman WM. Nat Commun. 2018 Jun 26; 2018 Jun 26. PMID: 29946143.
• Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing.Ricciardi AS, Quijano E, Putman R, Saltzman WM, Glazer PM. Molecules. 2018 Mar 11; 2018 Mar 11. PMID: 29534473.
• The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.Kim H, Lin Q, Glazer PM, Yun Z. Breast Cancer Res. 2018 Mar 6; 2018 Mar 6. PMID: 29510720.
• Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma.Scanlon SE, Hegan DC, Sulkowski PL, Glazer PM. Oncotarget. 2018 Jan 12; 2017 Dec 19. PMID: 29435132.
• Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities.Quijano E, Bahal R, Ricciardi A, Saltzman WM, Glazer PM. Yale J Biol Med. 2017 Dec; 2017 Dec 19. PMID: 29259523.
• Anti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy.Gupta A, Quijano E, Liu Y, Bahal R, Scanlon SE, Song E, Hsieh WC, Braddock DE, Ly DH, Saltzman WM, Glazer PM. Mol Ther Nucleic Acids. 2017 Dec 15; 2017 Sep 12. PMID: 29246289.
• A cell-penetrating antibody inhibits human RAD51 via direct binding.Turchick A, Hegan DC, Jensen RB, Glazer PM. Nucleic Acids Res. 2017 Nov 16. PMID: 29036688.
• Nickel induces transcriptional down-regulation of DNA repair pathways in tumorigenic and non-tumorigenic lung cells.Scanlon SE, Scanlon CD, Hegan DC, Sulkowski PL, Glazer PM. Carcinogenesis. 2017 Jun 1. PMID: 28472268.
• DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy.Nemec AA, Abriola L, Merkel JS, de Stanchina E, DeVeaux M, Zelterman D, Glazer PM, Sweasy JB. Mol Cancer Res. 2017 Mar; 2017 Jan 10. PMID: 28074003.
• 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS. Sci Transl Med. 2017 Feb 1. PMID: 28148839.
• Nanotechnology for delivery of peptide nucleic acids (PNAs).Gupta A, Bahal R, Gupta M, Glazer PM, Saltzman WM. J Control Release. 2016 Oct 28; 2016 Jan 8. PMID: 26776051.
• In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery.Bahal R, Ali McNeer N, Quijano E, Liu Y, Sulkowski P, Turchick A, Lu YC, Bhunia DC, Manna A, Greiner DL, Brehm MA, Cheng CJ, López-Giráldez F, Ricciardi A, Beloor J, Krause DS, Kumar P, Gallagher PG, Braddock DT, Mark Saltzman W, Ly DH, Glazer PM. Nat Commun. 2016 Oct 26; 2016 Oct 26. PMID: 27782131.
• miR-155 Overexpression Promotes Genomic Instability by Reducing High-fidelity Polymerase Delta Expression and Activating Error-Prone DSB Repair.Czochor JR, Sulkowski P, Glazer PM. Mol Cancer Res. 2016 Apr; 2016 Feb 5. PMID: 26850462.
• YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.Stachelek GC, Peterson-Roth E, Liu Y, Fernandez RJ 3rd, Pike LR, Qian JM, Abriola L, Hoyer D, Hungerford W, Merkel J, Glazer PM. Mol Cancer Res. 2015 Oct; 2015 Jun 26. PMID: 26116172.
• Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment.Scanlon SE, Glazer PM. DNA Repair (Amst). 2015 Aug; 2015 May 1. PMID: 25956861.
• DNA-dependent targeting of cell nuclei by a lupus autoantibody.Weisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE. Sci Rep. 2015 Jul 9; 2015 Jul 9. PMID: 26156563.
• Tumor suppressor p53 stole the AKT in hypoxia.Yun Z, Glazer PM. J Clin Invest. 2015 Jun; 2015 May 11. PMID: 25961449.
• Mechanism of action studies of lomaiviticin A and the monomeric lomaiviticin aglycon. Selective and potent activity toward DNA double-strand break repair-deficient cell lines.Colis LC, Hegan DC, Kaneko M, Glazer PM, Herzon SB. J Am Chem Soc. 2015 May 6; 2015 Apr 22. PMID: 25849366.
• Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium.McNeer NA, Anandalingam K, Fields RJ, Caputo C, Kopic S, Gupta A, Quijano E, Polikoff L, Kong Y, Bahal R, Geibel JP, Glazer PM, Saltzman WM, Egan ME. Nat Commun. 2015 Apr 27; 2015 Apr 27. PMID: 25914116.
• Modified poly(lactic-co-glycolic acid) nanoparticles for enhanced cellular uptake and gene editing in the lung.Fields RJ, Quijano E, McNeer NA, Caputo C, Bahal R, Anandalingam K, Egan ME, Glazer PM, Saltzman WM. Adv Healthc Mater. 2015 Feb 18; 2014 Aug 25. PMID: 25156908.
• MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ. Nature. 2015 Feb 5; 2014 Nov 17. PMID: 25409146.
• LKB1 preserves genome integrity by stimulating BRCA1 expression.Gupta R, Liu AY, Glazer PM, Wajapeyee N. Nucleic Acids Res. 2015 Jan; 2014 Dec 8. PMID: 25488815.
• Therapeutic genome mutagenesis using synthetic donor DNA and triplex-forming molecules.Reza F, Glazer PM. Methods Mol Biol. 2015. PMID: 25408401.
• Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1.Lu Y, Wajapeyee N, Turker MS, Glazer PM. Cell Rep. 2014 Jul 24; 2014 Jul 17. PMID: 25043185.
• microRNAs in cancer cell response to ionizing radiation.Czochor JR, Glazer PM. Antioxid Redox Signal. 2014 Jul 10; 2014 Feb 4. PMID: 24206455.
• HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSα.Zhang M, Xiang S, Joo HY, Wang L, Williams KA, Liu W, Hu C, Tong D, Haakenson J, Wang C, Zhang S, Pavlovicz RE, Jones A, Schmidt KH, Tang J, Dong H, Shan B, Fang B, Radhakrishnan R, Glazer PM, Matthias P, Koomen J, Seto E, Bepler G, Nicosia SV, Chen J, Li C, Gu L, Li GM, Bai W, Wang H, Zhang X. Mol Cell. 2014 Jul 3; 2014 May 29. PMID: 24882211.
• Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins.Scanlon SE, Glazer PM. Mol Cancer Res. 2014 Jul; 2014 Mar 31. PMID: 24688021.
• The cytotoxicity of (-)-lomaiviticin A arises from induction of double-strand breaks in DNA.Colis LC, Woo CM, Hegan DC, Li Z, Glazer PM, Herzon SB. Nat Chem. 2014 Jun; 2014 May 11. PMID: 24848236.
• Interplay between DNA repair and inflammation, and the link to cancer.Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, Sweasy JB. Crit Rev Biochem Mol Biol. 2014 Mar-Apr; 2014 Jan 13. PMID: 24410153.
• Single-stranded γPNAs for in vivo site-specific genome editing via Watson-Crick recognition.Bahal R, Quijano E, McNeer NA, Liu Y, Bhunia DC, Lopez-Giraldez F, Fields RJ, Saltzman WM, Ly DH, Glazer PM. Curr Gene Ther. 2014. PMID: 25174576.
• Targeted genome modification via triple helix formation.Ricciardi AS, McNeer NA, Anandalingam KK, Saltzman WM, Glazer PM. Methods Mol Biol. 2014. PMID: 25030921.
• Triplex-mediated genome targeting and editing.Reza F, Glazer PM. Methods Mol Biol. 2014. PMID: 24557900.
• Peptide nucleic acid-mediated recombination for targeted genomic repair and modification.Schleifman EB, Glazer PM. Methods Mol Biol. 2014. PMID: 24297362.
• Hypoxia and DNA repair.Glazer PM, Hegan DC, Lu Y, Czochor J, Scanlon SE. Yale J Biol Med. 2013 Dec 13; 2013 Dec 13. PMID: 24348208.
• Introduction.Sweasy JB, Glazer PM. Yale J Biol Med. 2013 Dec. PMID: 24498669.
• Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice.Schleifman EB, McNeer NA, Jackson A, Yamtich J, Brehm MA, Shultz LD, Greiner DL, Kumar P, Saltzman WM, Glazer PM. Mol Ther Nucleic Acids. 2013 Nov 19; 2013 Nov 19. PMID: 24253260.
• Radiation sensitivity and sensitization in melanoma.Shahbazian D, Bindra RS, Kluger HM, Glazer PM. Pigment Cell Melanoma Res. 2013 Nov; 2013 Aug 12. PMID: 23870422.
• Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo.McNeer NA, Schleifman EB, Cuthbert A, Brehm M, Jackson A, Cheng C, Anandalingam K, Kumar P, Shultz LD, Greiner DL, Mark Saltzman W, Glazer PM. Gene Ther. 2013 Jun; 2012 Oct 18. PMID: 23076379.
• Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5.Bahal R, McNeer NA, Ly DH, Saltzman WM, Glazer PM. Artif DNA PNA XNA. 2013 Apr-Jun. PMID: 23954968.
• Triplex-forming peptide nucleic acids induce heritable elevations in gamma-globin expression in hematopoietic progenitor cells.Chin JY, Reza F, Glazer PM. Mol Ther. 2013 Mar; 2013 Jan 22. PMID: 23337982.
• Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.Neumeister VM, Sullivan CA, Lindner R, Lezon-Geyda K, Li J, Zavada J, Martel M, Glazer PM, Tuck DP, Rimm DL, Harris L. Breast Cancer Res Treat. 2012 Nov; 2012 Sep 14. PMID: 22976806.
• Targeting cancer with a lupus autoantibody.Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Sci Transl Med. 2012 Oct 24. PMID: 23100628.
• Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP. Mol Cancer Ther. 2012 Mar; 2011 Dec 6. PMID: 22147748.
• Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.Rockwell S, Liu Y, Seow HA, Ishiguro K, Baumann RP, Penketh PG, Shyam K, Akintujoye OM, Glazer PM, Sartorelli AC. Int J Radiat Biol. 2012 Mar; 2011 Dec 20. PMID: 22111842.
• Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate.Rogers FA, Lin SS, Hegan DC, Krause DS, Glazer PM. Mol Ther. 2012 Jan; 2011 Aug 9. PMID: 21829173.
• Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage.Lin ZP, Lee Y, Lin F, Belcourt MF, Li P, Cory JG, Glazer PM, Sartorelli AC. Mol Pharmacol. 2011 Dec; 2011 Aug 29. PMID: 21875941.
• Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells.Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ. Cancer Biol Ther. 2011 Nov 15; 2011 Nov 15. PMID: 22027557.
• Functional and physical interaction between the mismatch repair and FA-BRCA pathways.Williams SA, Wilson JB, Clark AP, Mitson-Salazar A, Tomashevski A, Ananth S, Glazer PM, Semmes OJ, Bale AE, Jones NJ, Kupfer GM. Hum Mol Genet. 2011 Nov 15; 2011 Aug 24. PMID: 21865299.
• Polymer delivery systems for site-specific genome editing.McNeer NA, Schleifman EB, Glazer PM, Saltzman WM. J Control Release. 2011 Oct 30; 2011 May 18. PMID: 21620910.
• Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids.Schleifman EB, Bindra R, Leif J, del Campo J, Rogers FA, Uchil P, Kutsch O, Shultz LD, Kumar P, Greiner DL, Glazer PM. Chem Biol. 2011 Sep 23. PMID: 21944757.